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Purpose: The purpose of the current study was to investigate the effect of topical administration of KH906 on corneal
neovascularization (NV).
Methods: To induce corneal neovascularization, chemical cauterization of the corneas of the right eyes of forty-eight
New Zealand white rabbits was performed by touching the central cornea with an 8-mm-diameter NaOH-soaked Whatman
filter paper for 60 s. On the next day after modeling, the rabbits were randomly and equally divided into six groups: PBS
control group, 0.1% dexamethasone group, 10 mg/ml Avastin group, 5 mg/ml KH906 group, 10 mg/ml KH906 group,
and 20 mg/ml KH906 group. The rabbits in the six groups received topical administration of 50 μl of the different solutions
on the cornea four times per day for 14 days. Corneal neovascularization was analyzed by slit-lamp biomicroscopy 10
and 14 days after chemical cauterization. Corneal fluorescein staining was performed to evaluate the extent of corneal
epithelial defect on the 7th, 10th, and 14th days. The VEGF level of the cornea was evaluated by ELISA assay.
Results: On the 10th and 14th days after chemical cauterization, the length of the longest new vessel and the areas of
corneal neovascularization in all KH906-treated groups were significantly reduced compared to those of the PBS-treated
group (p<0.05). The VEGF level of the cornea in all KH906-treated groups was significantly decreased compared to that
of the PBS-treated group (p<0.05). Corneal fluorescein staining showed that KH906 had no effect on corneal epithelial
healing.
Conclusions: Topical administration of KH906 significantly inhibited alkali burn-induced corneal neovascularization in
rabbits. The new eye drops of KH906 may have a broad application for human corneal neovascularization in the near
future.
In normal physiologic status, the cornea is transparent to
maintain  normal  vision.  Corneal  neovascularization  is  a
concomitant complication of many ocular surface diseases. It
significantly diminishes corneal clarity and is a cause of a
subsequent  reduction  in  vision  [1].  Meanwhile,  corneal
neovascularization is the major reason for corneal allograft
rejection  [2,3].  Various  treatments  including  drugs  and
surgery  have  been  applied  in  treating  corneal
neovascularization. Surgical operations such as radiotherapy,
laser therapy, photodynamic therapy, and diathermy are very
complicated. Drugs including steroids, methotrexate, heparin,
cyclosporine A, and thalidomide are used but do not currently
produce an ideal clinical effect [1,4-7]. Recently, vascular
endothelial growth factor (VEGF) has been proven a major
inducer of corneal neovascularization [7-9]. VEGF and its
tyrosine kinase receptors (flt-1 and KDR) are key mediators
in angiogenesis.
Corneal  neovascularization  occurs  as  a  result  of  a
disequilibrium  between  angiogenic  and  antiangiogenic
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factors [4]. Anti-VEGF treatment has shown great results in
many  animal  models  and  clinical  trials  [10,11].  Avastin
(Bevacizumab; Genentech, San Francisco, CA) is a typical
anti-angiogenesis medicine that has entered the clinical trial
stage  to  treat  corneal  neovascularization.  This  drug  is  a
recombinant humanized monoclonal IgG1 antibody with a
93% human and 7% murine protein sequence. Avastin binds
to all five VEGF-A isoforms. It is already being administered
intravitreally  for  the  treatment  of  exudative  age-related
macular degeneration, proliferative diabetic retinopathy, and
iris  rubeosis  with  good  results  [12-15].  Subconjunctival
administration  of  Avastin  in  experimental  animal  models
could inhibit corneal neovascularization [16-18].
KH906, a recombinant human soluble endothelial growth
factor (VEGF) receptor fusion protein with a 100% human
protein  sequence,  is  the  patented  product  of  Chengdu
Kanghong Biotechnology Co. Ltd. (Chengdu, China). KH906
contains  extracellular  ligand-binding  domain  3,  4  from
VEGFR2/KDR, domain 2 from VEGFR1/ Flt-1, and human
IgG Fc protein. A VEGF binding assay and a VEGF-induced
HUVECs proliferation assay demonstrated that KH906 could
bind  VEGF  with  a  very  high  affinity  and  inhibit  VEGF-
induced HUVECs proliferation. KH906 binds to not only all
VEGF-A isoforms, but also VEGF-B and VEGF-C, so it has
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797a stronger anti-angiogenesis effect than Avastin in theory.
KH902  (Chengdu  Kanghong  Biotechnology  Co.  Ltd.,
Chengdu, China), another molecule with the same amino acid
sequence  but  different  production  processes  and
glycosylation,  was  proven  effective  in  animal  models  for
treating choroidal neovascularization (CNV) [19]. Therefore,
this study was designed to investigate the effect of the topical
administration of KH906 on the prevention of alkali burn-
induced corneal neovascularization in a rabbit model.
METHODS
Animals: This study was approved by the Institutional Animal
Care and Use Committee of Zhongshan Ophthalmic Center,
Sun Yat-sen University, Guangzhou, China. All experimental
procedures on animals were conducted in accordance with the
Association  for  Research  in  Vision  and  Ophthalmology
Resolution on the use of animals in research. Forty-eight New
Zealand white rabbits weighing between 2.2 kg and 2.5 kg
were used in the study. The animals were housed under a 12
h:12 h light-dark cycle with standard chow and water ad
libitum.
Induction of corneal neovascularization: General anesthesia
was induced by an intramuscular injection of ketamine HCl
(2 mg/kg bodyweight) and chlorpromazine HCl (2 mg/kg
bodyweight) [20]. At the same time, more than 50 round filter
papers  (8-mm  diameter)  were  prepared  and  immersed  in
10 μl 1M NaOH for 10 s. While the animals were under
general anesthesia, the NaOH-soaked filter paper was placed
on the center of the cornea surface of the right eyes of the
rabbits for 60 s. Then, the eyes were rinsed thoroughly with
more than 50 ml sterile normal saline. To prevent potential
infection, all burned eyes were treated with erythromycin eye
ointment. To increase the reproducibility of the alkali burn,
the whole process was performed on each rabbit by the same
investigator.
Groups and topical administration of solutions on corneas:
On the next day after modeling, the rabbits were randomly
divided  into  six  groups:  PBS  control  group,  0.1%
dexamethasone group, 10 mg/ml Avastin group, 5 mg/ml
KH906 group, 10 mg/ml KH906 group, and 20 mg/ml KH906
group.  The  rabbits  in  the  six  groups  received  topical
administration of 50 μl of different solutions on the cornea
four times per day for 14 days.
Observation  and  examination:  The  chemical  cauterization
modeling day was taken as day 0. All eyes were examined
daily,  and  major  reports  on  the  development  of  corneal
neovascularization were made 10 and 14 days after chemical
cauterization by slit-lamp examination (SL-120; Zeiss, Jena,
Germany). To minimize observer bias, all observations were
performed by an eye doctor who was blinded to the allocation
of  the  animals  in  each  group.  Digital  photographs  were
obtained with a Nikon megapixels digital camera (D90; Nikon
imaging [China] Sales Co. Ltd, Beijing, China). The area of
corneal  neovascularization  was  determined  using  the
following  formula:  AC=C/12×3.1416×[r2-  (r-L)  2]  [21,22]
where  C  represents  the  clock  hours  of  corneal
neovascularization,  r  represents  the  radius  of  the  animal
cornea, and L represents the length of the longest new vessel.
The length of vessel was measured with a reticule from the
limbus to the tip of the vessel. All photographs were evaluated
by two investigators.
On day 15 after chemical cauterization, all animals were
sacrificed, and the corneas were harvested. The homogenate
of each cornea was taken for the ELISA assay to examine
VEGF levels with a fully automatic enzyme-linked analyzer.
In addition, corneal fluorescein staining with fluorescein
sodium was performed on the 7th, 10th, and 14th days to
evaluate  corneal  epithelial  healing.  The  area  of  epithelial
defect was measured using Image-Pro Plus 6.0 software.
Statistical analysis: All data in each group was reported as the
mean±SD. The significant differences between the treated and
control groups were determined using the one-way ANOVA.
Statistical  analysis  was  performed  using  SPSS  software
version 16.0 for Windows (SPSS Inc., Chicago, IL). A value
of p<0.05 was considered significant.
RESULTS
Corneal  neovascularization  after  alkali  burn:  During  the
entire  experimental  period,  no  endophthalmitis  or
inflammation  of  the  ocular  surface  was  observed.  In  the
corneal alkali burn model, neovascular began to form within
the first week, and mild peripheral neovascularization was
apparent on the 7th day. The vessels that emerged from the
adjacent limbus appeared short, fine, and dense. Two weeks
after  cauterization,  there  was  clear  evidence  of
neovascularization with major visible vessels. The corneal
neovascularization of the PBS control group (PBS), 0.1%
dexamethasone group (DEX), 10 mg/ml Avastin group (AV),
5 mg/ml KH906 group (K-5), 10 mg/ml KH906 group (K-10),
and 20 mg/ml KH906 group (K-20) on the 10th and 14th days
are shown in Figure 1A.
On the 10th day after cauterization, the length of the
longest  new  vessel  showed  a  significant  decrease  in  all
medicine-treated  groups  compared  with  the  PBS  control
group  (AV=0.88±0.57  mm,  K-5=0.97±0.52  mm,
K-10=0.80±0.84 mm *p<0.05 versus PBS=1.85±0.67 mm ;
DEX=0.29±0.09 mm, K-20=0.32±0.33 mm #p<0.05 versus
PBS). The 0.1% dexamethasone-treated group and the 20 mg/
ml KH906-treated group showed greater results than the other
medicine-treated groups. On the 14th day after cauterization,
the length of the longest new vessel also showed a significant
decrease in all medicine-treated groups compared with the
PBS control group (AV=1.36±1.40 mm, K-5=1.40±1.38 mm,
K-10=1.25±0.94 mm, K-20=1.17±0.61 mm *p<0.05 versus
PBS=2.53±1.23 mm; DEX=0.32±0.18 mm, #p<0.05 versus
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798PBS). The 0.1% dexamethasone-treated group showed greater
results than the other medicine-treated groups (Figure 1B).
On  the  10  th  day  after  cauterization,  the  area  of
vascularized  cornea  showed  a  significant  decrease  in  all
medicine-treated  groups  compared  with  the  PBS  control
group  (AV=6.85±3.96 mm2,             K-5=8.47±3.58 mm2,
K-10=5.75±3.70 mm2   *p<0.05 versus PBS=21.31±4.51 mm ;
 
2
  DEX=3.91±2.75  mm2   ,  K-20=2.07±2.32   mm  #      p<0.05  2
  versus PBS). The  0.1%  dexamethasone-treated  group   and
  the    20   mg/ml    KH906-treated    group    showed    greater
results      than      the      other      medicine-treated      groups. 
On     the     14th     day     after    cauterization,     the     area     of
vascularized cornea also showed a significant decrease in all
medicine-treated  groups  compared  with  the  PBS  control
group  (AV=10.45±4.50  mm2,  K-5=10.92±6.58  mm2,
K-10=10.08±5.13  mm2,  K-20=9.53±4.22  mm2  *p<0.05
versus  PBS=22.06±7.61  mm2  ;  DEX=5.00±3.13  mm2,
#p<0.05  versus  PBS).  The  0.1%  dexamethasone-treated
group showed greater results than the other medicine-treated
groups (Figure 1C).
VEGF ELISA assay: VEGF levels in the homogenate of the
cornea showed a significant decrease in all medicine-treated
groups  compared  with  those  of  the  PBS  control  group
(AV=1.90±0.40 ng/g, K-5=1.69±0.62 ng/g, K-10=1.58±0.26
Figure 1. Corneal NV induced by alkali burn. A: slit-lamp photograph of corneal NV on the 10th and 14th days after chemical cauterization.
The NV of the PBS-treated group was dense, fine, and almost reached to the central cornea. The NV of all KH906-treated groups and the
Avastin-treated group was less dense and shorter than that of the PBS group. The inhibitive effect on NV in the dexamethasone-treated group
was the best. B: The length of the longest vessel in all groups on the 10th and 14th days. The mean length of the longest new vessel in all
medicine-treated groups was shorter than that of the PBS control group on both the 10th and 14th days after cauterization (p<0.05). The vessel
length was shortest in both the dexamethasone-treated group and the KH906 (20 mg/ml)-treated group, and there was a statistically significant
difference between the two groups and the other groups on the 10th day (p<0.05). Meanwhile, only the length of the longest vessel in the
dexamethasone-treated group differed significantly from those of the other medicine-treated groups on the 14th day (p<0.05). C: Area of
corneal NV in all groups on the 10th and 14th days. The change in the area of corneal NV showed the same trend as that of the length of the
longest new vessel. PBS: PBS, DEX: dexamethasone, AV: Avastin, K-5:KH906 (5 mg/ml), K-10:KH906 (10 mg/ml), K-20:KH906 (20 mg/
ml). *There is a statistically significant difference between groups with a *symbol and groups without a *symbol. #There is a statistically
significant difference between groups with a #symbol and groups without a #symbol.
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799ng/g, K-20=1.45±0.64 ng/g *p<0.05 versus PBS=2.28±0.29
ng/g; DEX=0.88±0.30 ng/g #p<0.05 versus PBS). The VEGF
level was lowest in the dexamethasone-treated group. There
was  no  statistically  significant  difference  between  the
Avastin-treated group and the KH906-treated groups (p>0.05;
Figure 2).
Corneal fluorescein staining:  Corneal fluorescein staining
showed the effect of topical use of KH906 and other medicines
on corneal wound healing after alkali burn. Results indicated
that corneal damage can be repaired by the self-repair function
of  the  cornea  after  alkali  burn.  The  PBS  group  and  all
medicine-treated  groups  except  for  the  dexamethasone-
treated group showed fine healing processes after alkali burn
(Figure 3A).
On the 7th day after cauterization, the area of epithelial
defect was larger in the dexamethasone-treated group than in
the other groups (PBS=2.82±0.27 mm2, AV=2.7±0.11 mm2,
K-5=2.63±0.35 mm2, K-10=2.61±0.37 mm  2,     K-20=2.74±
0.66 mm2   *     p<0.05    versus    DEX=16.27±    1.78 mm  ). 2
 On the 10th day after cauterization, there was a statistically
significant  difference  between the dexamethasone-treated
  group and the other groups (PBS=2.02±0.16 mm  AV=1.97±
 
2
 0.06 mm2, K-5=1.84±0.44 mm  ,        K-10=1.98±0.27 mm 2 2,
K-20=2.01±0.36 mm2   *p<0.05     versus      DEX=27.92.91±
2 2.40 mm  ). The  same     trend    (PBS=0.94±0.08 mm  , 2
AV=0.99±0.23 mm2,                           K-5=0.92±0.17 mm  , 2
K-10=0.99±0.24 mm2, K-20=0.96±0.08 mm *p<0.05 versus 2
  DEX=27.92±2.40 mm2) was apparent on the 14th day after
cauterization (Figure 3B).
DISCUSSION
Many  ocular  surface  diseases,  such  as  inflammatory,
infectious, degenerative, and traumatic disorders, will induce
corneal  neovascularization  [23].  Although  corneal
neovascularization  may  play  a  certain  role  in  infection
removal and wound healing, it can destroy the normal corneal
microenvironment and lead to the loss of the immune privilege
of  the  cornea.  The  direct  negative  result  of  corneal
neovascularization is the loss of corneal transparency, which
is  critical  for  vision.  What  is  more,  serious  corneal
neovascularization can lead to blindness.
Many drugs and operations are presently being used to
treat  corneal  neovascularization.  Steroids  remain  the  first
choice in clinical treatment on corneal neovascularization,
because neovascularization is assumed to be secondary to
some degree of inflammation. However, steroids are not ideal
in treating corneal neovascularization, as they can cause the
replication of pathogens such as fungus and herpes simplex
virus  and  retard  corneal  wound  healing  [24-26].  Besides,
steroid treatment may cause glaucoma and cataract. These
side  effects  limit  the  application  of  steroids  in  corneal
neovascularization. When inflammation is not the main cause
of angiogenesis, such as in diseases associated with deficiency
of  limbal  cells  or  corneal  hypoxia,  anti-inflammatory
corticosteroids have little or no effect on capillary growth
[16]. Laser photocoagulation, diathermy, and photodynamic
therapy are also effective in the obliteration of local corneal
Figure 2. VEGF levels in the cornea.
The results showed that the VEGF levels
of  all  medicine-treated  groups
obviously decreased compared to that of
the  PBS  group  (p<0.05).  The  VEGF
level was lowest in the dexamethasone-
treated  group,  and  there  was  a
statistically  significant  difference
between  the  dexamethasone-treated
group and the other groups (p<0.05). All
doses  of  KH906  decreased  VEGF
levels.  There  was  no  statistically
significant  difference  between  the
Avastin-treated group and the KH906-
treated  groups  (p>0.05).  PBS:  PBS,
DEX:  dexamethasone,  AV:  Avastin,
K-5:KH906  (5  mg/ml),  K-10:KH906
(10 mg/ml), K-20:KH906 (20 mg/ml).
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800neovascularization [27-30]. Although favorable results have
been obtained with these techniques, they are not available for
extensive corneal neovascularization and have complicated
manipulations [31]. For all the above reasons, more effective,
easier  and  safer  corneal  neovascularization  treatment  is
required.
Recently, researchers found that VEGF acts as the key
mediator  during  inflammation  and  neovascularization.  It
regulates the growth of vascular endothelium and controls the
formation of new blood vessels [32]. VEGF is secreted mainly
from macrophages, T cells, retinal pigment epithelial cells,
smooth muscle cells, and tumor cells with the stimulation of
various environmental factors, especially hypoxia. Binding to
its receptors, VEGF triggers a signaling cascade that promotes
endothelial cell growth, survival, migration, differentiation,
and mobilization of endothelial progenitor cells from the bone
marrow  into  the  peripheral  circulation  [33].  Several  anti-
VEGF drugs have been tested as treatments for angiogenesis
diseases. Avastin, Lucentis, Macugen, and VEGF-Trap have
been  applied  in  treating  cancer,  neovascular  age-related
macular  degeneration,  diabetic  retinopathy,  neovascular
glaucoma,  and  corneal  neovascularization.  Avastin  is
considered one of the most effective medicines. In this study,
we compared the effects of topical administration of KH906
with those of Avastin on treating corneal neovascularization.
Our results proved that both KH906 and Avastin could
inhibit  corneal  neovascularization  equally  with  the  same
decrease of VEGF level in cornea. At the same dose of tropic
administration on cornea, there was no statistically significant
difference  on  inhibiting  the  corneal  neovascularization
between  KH906-treated  group  and  Avastin-treated  group.
KH906  was  proved  very  effective  in  preventing
neovascularization when administered topically. The length
and area of corneal neovascularization decreased significantly
compared  with  the  PBS  control  group.  Although  KH906
seemed less effective than dexamethasone, its safety makes it
a promising drug. In our study, corneal fluorescein staining
showed that the topical use of KH906 had no side effects on
the processes of corneal wound healing, but dexamethasone
seriously influenced corneal wound healing. As we discussed
above, the side effects limit the applications of steroids in
corneal  neovascularization.  KH906  is  a  fully  humanized
protein that can be absorbed without obvious side effects.
To conclude, topical administration of KH906 is effective
in  treating  corneal  neovascularization  in  the  rabbit
experimental model. No adverse effects on the cornea were
found.  More  research  is  needed  to  define  the  ideal
concentration and time of administration of KH906 to achieve
the best clinical outcome. The new eye drops of KH906 may
Figure 3. Corneal fluorescein staining on the 7th, 10th, and 14th days after chemical cauterization. A: Slit-lamp photograph of corneal
fluorescein staining on day 10. The recovery of the corneal epithelium was strongly delayed in the dexamethasone-treated group. B: A statistical
comparison of the area of corneal epithelial defect on the 7th, 10th, and 14th days after chemical cauterization. There was a statistically
significant difference between the dexamethasone-treated group and the other groups. PBS: PBS, DEX: dexamethasone, AV: Avastin,
K-5:KH906 (5 mg/ml), K-10:KH906 (10 mg/ml), K-20:KH906 (20 mg/ml).
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801have a broad application in the treatment of human corneal
neovascularization in the near future.
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